Conditions: Attention Deficit Hyperactivity Disorder
Keywords: Hyperactivity Attention Deficit Disorder ADHD Pediatric Patients Quillivant methylphenidate
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 45
Healthy volunteers: no

Brief summary:
The objective of this study was to establish that an optimal dose of Quillivant XR oral suspension would result in a significant reduction in signs and symptoms of ADHD compared to placebo treatment in pediatric patients ages 6-12 years with ADHD.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Quillivant Oral Suspension XR intervention 2: Placebo intervention 3: Placebo
Intervention descriptions: intervention 1: Oral Suspension 25mg/5mL; 20-60 mg/day intervention 2: Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day intervention 3: Matching placebo was a solution that was identical in taste and appearance to the Active drug that was used in this study.

Protocol document: